BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Parra-Herran C, Quick CM, Howitt BE, Dal Cin P, Quade BJ, Nucci MR. Inflammatory myofibroblastic tumor of the uterus: clinical and pathologic review of 10 cases including a subset with aggressive clinical course. Am J Surg Pathol 2015;39:157-68. [PMID: 25321329 DOI: 10.1097/PAS.0000000000000330] [Cited by in Crossref: 79] [Cited by in F6Publishing: 83] [Article Influence: 9.9] [Reference Citation Analysis]
Number Citing Articles
1 Ladwig NR, Bean GR, Pekmezci M, Boscardin J, Joseph NM, Therrien N, Sangoi AR, Piening B, Rajamanickam V, Galvin M, Bernard B, Zaloudek C, Rabban JT, Garg K, Umetsu SE. Uterine Inflammatory Myofibroblastic Tumors: Proposed Risk Stratification Model Using Integrated Clinicopathologic and Molecular Analysis. Am J Surg Pathol 2023;47:157-71. [PMID: 36344483 DOI: 10.1097/PAS.0000000000001987] [Reference Citation Analysis]
2 Karpathiou G, Devouassoux-Shisheboran M, Stolnicu S, Chauleur C, Péoc'h M. Uterine inflammatory myofibroblastic tumor. Pathol Res Pract 2023;242:154335. [PMID: 36706588 DOI: 10.1016/j.prp.2023.154335] [Reference Citation Analysis]
3 Zhang L, Luan L, Shen L, Xue R, Huang J, Su J, Huang Y, Xu Y, Wang X, Shao Y, Ji Y, Xu C, Hou Y. Uterine inflammatory myofibroblastic tumor harboring novel NUDCD3-ROS1 and NRP2-ALK fusions: clinicopathologic features of 4 cases and literature review. Virchows Arch 2023. [PMID: 36624188 DOI: 10.1007/s00428-022-03457-7] [Reference Citation Analysis]
4 Horwood G, Busca A, Singh S. Fertility-preserving management of an inflammatory myofibroblastic tumor: A case report and review of the literature. Case Reports in Women's Health 2023. [DOI: 10.1016/j.crwh.2023.e00481] [Reference Citation Analysis]
5 Bowman CJ, Medeiros F, Fadare O, Sangoi AR, Horvai AE, Devine WP, McCluggage WG, Rabban JT. ALK Immunoexpression is Specific for Inflammatory Myofibroblastic Tumor Among Vulvovaginal Mesenchymal Neoplasms. Int J Gynecol Pathol 2023;42:1-10. [PMID: 35180768 DOI: 10.1097/PGP.0000000000000858] [Reference Citation Analysis]
6 Tang F, Dai G, Huang X, Wang D. Uterine inflammatory myofibroblastic tumor presented as abnormal uterine bleeding: Two cases report and literature review. Medicine (Baltimore) 2022;101:e32141. [PMID: 36550868 DOI: 10.1097/MD.0000000000032141] [Reference Citation Analysis]
7 Chang B, Wang Z, Ren M, Yao Q, Zhao L, Zhou X. A Novel CASC15-ALK and TFG-ROS1 Fusion Observed in Uterine Inflammatory Myofibroblastic Tumor. Int J Gynecol Pathol 2022. [PMID: 36730016 DOI: 10.1097/PGP.0000000000000926] [Reference Citation Analysis]
8 Liu X, Duan Y, Wang G, Zhu P. A novel TPD52L2-ROS1 gene fusion expanding the molecular alterations in inflammatory myofibroblastic tumor: case report and literature review.. [DOI: 10.21203/rs.3.rs-2290230/v1] [Reference Citation Analysis]
9 Nucci MR, Webster F, Croce S, George S, Howitt BE, Ip PP, Lee C, Rabban JT, Soslow RA, van der Griend R, Lax SF, Mccluggage WG. Data Set for Reporting of Uterine Malignant and Potentially Malignant Mesenchymal Tumors: Recommendations From the International Collaboration on Cancer Reporting (ICCR). International Journal of Gynecological Pathology 2022;41:S44-S63. [DOI: 10.1097/pgp.0000000000000911] [Reference Citation Analysis]
10 Croce S, Devouassoux-Shisheboran M, Pautier P, Ray-Coquard I, Treilleux I, Neuville A, Arnould L, Just PA, Belda MALF, Averous G, Leroux A, Mery E, Loussouarn D, Weinbreck N, Le Guellec S, Mishellany F, Morice P, Guyon F, Genestie C. Uterine sarcomas and rare uterine mesenchymal tumors with malignant potential. Diagnostic guidelines of the French Sarcoma Group and the Rare Gynecological Tumors Group. Gynecol Oncol 2022:S0090-8258(22)00515-7. [PMID: 36114030 DOI: 10.1016/j.ygyno.2022.07.031] [Reference Citation Analysis]
11 Boyraz B, Post MD, Hasserjian RP, Oliva E. Follicular Dendritic Cell Sarcoma of Uterine Corpus: Report of 2 Cases. Int J Gynecol Pathol 2022. [PMID: 36044301 DOI: 10.1097/PGP.0000000000000903] [Reference Citation Analysis]
12 Schwartz C, Gundogan F, Singh K, Schoolmeester JK, Banet N. Inflammatory Myofibroblastic Tumor of the Placenta With Subsequent Successful Pregnancy and Benign Hysterectomy: A Case Report With 59-Month Follow-up. Int J Gynecol Pathol 2022. [PMID: 35838599 DOI: 10.1097/PGP.0000000000000893] [Reference Citation Analysis]
13 Costigan DC, Nucci MR, Dickson BC, Chang MC, Song S, Sholl LM, Hornick JL, Fletcher CDM, Kolin DL. NTRK -Rearranged Uterine Sarcomas: Clinicopathologic Features of 15 Cases, Literature Review, and Risk Stratification. Am J Surg Pathol 2022;46:1415-29. [PMID: 35713627 DOI: 10.1097/PAS.0000000000001929] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Watkins JC, Roberts DJ. Placenta-associated uterine inflammatory myofibroblastic tumor with a novel FBLN1-ALK1 fusion. Human Pathology Reports 2022;28:300647. [DOI: 10.1016/j.hpr.2022.300647] [Reference Citation Analysis]
15 Kertowidjojo EC, Bennett JA. Update on Uterine Mesenchymal Neoplasms. Surgical Pathology Clinics 2022. [DOI: 10.1016/j.path.2022.02.008] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
16 Kuisma H, Jokinen V, Pasanen A, Heikinheimo O, Karhu A, Välimäki N, Aaltonen L, Bützow R. Histopathologic and Molecular Characterization of Uterine Leiomyoma–like Inflammatory Myofibroblastic Tumor: Comparison to Molecular Subtypes of Uterine Leiomyoma. American Journal of Surgical Pathology 2022;Publish Ahead of Print. [DOI: 10.1097/pas.0000000000001904] [Reference Citation Analysis]
17 Ng ZY, Khaing CT, Aggarwal I. Inflammatory myofibroblastic tumor: an under recognized differential of uterine mesenchymal tumors. Int J Gynecol Cancer 2022;32:212-3. [DOI: 10.1136/ijgc-2021-003247] [Reference Citation Analysis]
18 Wei J. Leiomyoma with nuclear atypia: Rare diseases that present a common diagnostic problem. Seminars in Diagnostic Pathology 2022. [DOI: 10.1053/j.semdp.2022.01.006] [Reference Citation Analysis]
19 张 艳. A Case of Uterine Inflammatory Myofibroblastic Tumor. ACM 2022;12:4978-4982. [DOI: 10.12677/acm.2022.126721] [Reference Citation Analysis]
20 Chiang S. Mesenchymal Tumors, Pathology of the Uterine Corpus. Encyclopedia of Pathology 2022. [DOI: 10.1007/978-3-319-28845-1_5626-1] [Reference Citation Analysis]
21 Niu S, Zheng W. Endometrial stromal tumors: Diagnostic updates and challenges. Seminars in Diagnostic Pathology 2022. [DOI: 10.1053/j.semdp.2022.01.004] [Reference Citation Analysis]
22 Chapel DB, Nucci MR. An update in pathologic diagnosis of uterine mesenchymal tumours. Diagnostic Histopathology 2021;27:506-518. [DOI: 10.1016/j.mpdhp.2021.09.005] [Reference Citation Analysis]
23 López de Sa A, Pascual A, Garcia Santos J, Mendez R, Bellon M, Ramirez M, Matute F, Del Arco C, Manzano A, Coronado P, Casado A, Marquina G. Inflammatory myofibroblastic tumour of an unusual presentation in the uterine cervix: a case report. World J Surg Oncol 2021;19:331. [PMID: 34801049 DOI: 10.1186/s12957-021-02438-5] [Reference Citation Analysis]
24 Sanaya SZ, Matsneva IA, Redkina NA, Telezhnikova IM, Magnaeva AS, Tregubova AV, Asaturova AV, Kometova VV. [Immunohistochemical and molecular diagnosis of inflammatory myofibroblastic tumor of the uterus: a literature review and a clinical case]. Arkh Patol 2021;83:43-8. [PMID: 34609804 DOI: 10.17116/patol20218305143] [Reference Citation Analysis]
25 Parenchyma. Atlas of Placental Pathology 2021. [DOI: 10.55418/9781933477091-ch08] [Reference Citation Analysis]
26 Walsh EM, Xing D, Lippitt MH, Fader AN, Wethington SL, Meyer CF, Gaillard SL. Molecular Tumor Board Guides Successful Treatment of a Rare, Locally Aggressive, Uterine Mesenchymal Neoplasm. JCO Precis Oncol 2021;5:PO. [PMID: 34250413 DOI: 10.1200/PO.20.00189] [Reference Citation Analysis]
27 Wei J, Purdy J. Uterine Mesenchymal Neoplasia. Practical Gynecologic Pathology 2021. [DOI: 10.1007/978-3-030-68608-6_6] [Reference Citation Analysis]
28 Euscher ED, Buza N, Hui P. Immunohistochemistry. Practical Gynecologic Pathology 2021. [DOI: 10.1007/978-3-030-68608-6_15] [Reference Citation Analysis]
29 Hirsch MS, Watkins J. A Comprehensive Review of Biomarker Use in the Gynecologic Tract Including Differential Diagnoses and Diagnostic Pitfalls. Adv Anat Pathol 2020;27:164-92. [PMID: 31149908 DOI: 10.1097/PAP.0000000000000238] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
30 Arias-Stella JA 3rd, Benayed R, Oliva E, Young RH, Hoang LN, Lee CH, Jungbluth AA, Frosina D, Soslow RA, Antonescu CR, Ladanyi M, Chiang S. Novel PLAG1 Gene Rearrangement Distinguishes a Subset of Uterine Myxoid Leiomyosarcoma From Other Uterine Myxoid Mesenchymal Tumors. Am J Surg Pathol 2019;43:382-8. [PMID: 30489320 DOI: 10.1097/PAS.0000000000001196] [Cited by in Crossref: 33] [Cited by in F6Publishing: 23] [Article Influence: 11.0] [Reference Citation Analysis]
31 Mccluggage WG. Immunohistochemistry and Molecular Diagnostics in the Differential Diagnosis of Female Genital Tract Pathology. Gynecologic Pathology 2020. [DOI: 10.1016/b978-0-323-35909-2.00020-5] [Reference Citation Analysis]
32 Malpica A, Euscher ED, Ramalingam P, Aguilera-barrantes I, Alvarado-cabrero I. Gynecological Pathology. Oncological Surgical Pathology 2020. [DOI: 10.1007/978-3-319-96681-6_15] [Reference Citation Analysis]
33 Parra-herran C. Mesenchymal and Miscellaneous Lesions of the Uterus. Gynecologic Pathology 2020. [DOI: 10.1016/b978-0-323-35909-2.00011-4] [Reference Citation Analysis]
34 Oliva E, Zaloudek CJ, Soslow RA. Mesenchymal Tumors of the Uterus. In: Kurman RJ, Hedrick Ellenson L, Ronnett BM, editors. Blaustein's Pathology of the Female Genital Tract. Cham: Springer International Publishing; 2019. pp. 535-647. [DOI: 10.1007/978-3-319-46334-6_10] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
35 Chiang S, Martelotto LG, Weigelt B. Genomic Applications in Gynecologic Malignancies. Genomic Applications in Pathology 2019. [DOI: 10.1007/978-3-319-96830-8_31] [Reference Citation Analysis]
36 Howitt BE, Nucci MR. Uterine Mesenchymal Lesions. Gynecologic and Obstetric Pathology, Volume 2 2019. [DOI: 10.1007/978-981-13-3019-3_1] [Reference Citation Analysis]
37 Fadare O, Roma AA. Mesenchymal and Miscellaneous Neoplasms of the Uterine Corpus. Atlas of Anatomic Pathology 2019. [DOI: 10.1007/978-3-030-17931-1_5] [Reference Citation Analysis]
38 Fetsch JF, Laskin WB. Soft Tissue Lesions Involving Female Reproductive Organs. Blaustein's Pathology of the Female Genital Tract 2019. [DOI: 10.1007/978-3-319-46334-6_22] [Reference Citation Analysis]
39 Dei Tos AP. Intermediate Malignant and Malignant Tumors of Soft Tissue Featuring an Inflammatory Background. Soft Tissue Sarcomas 2018. [DOI: 10.1017/9781316535097.011] [Reference Citation Analysis]
40 Oliva E, Zaloudek CJ, Soslow RA. Mesenchymal Tumors of the Uterus. Blaustein's Pathology of the Female Genital Tract 2018. [DOI: 10.1007/978-1-4614-3165-7_10-2] [Reference Citation Analysis]
41 Howitt BE, Nucci MR, Quade BJ. Uterine Mesenchymal Tumors. Diagnostic Gynecologic and Obstetric Pathology 2018. [DOI: 10.1016/b978-0-323-44732-4.00020-0] [Reference Citation Analysis]
42 Fetsch JF, Laskin WB. Soft Tissue Lesions Involving Female Reproductive Organs. Blaustein's Pathology of the Female Genital Tract 2018. [DOI: 10.1007/978-1-4614-3165-7_22-2] [Reference Citation Analysis]
43 Lewis N, Soslow RA, Delair DF, Park KJ, Murali R, Hollmann TJ, Davidson B, Micci F, Panagopoulos I, Hoang LN, Arias-Stella JA 3rd, Oliva E, Young RH, Hensley ML, Leitao MM Jr, Hameed M, Benayed R, Ladanyi M, Frosina D, Jungbluth AA, Antonescu CR, Chiang S. ZC3H7B-BCOR high-grade endometrial stromal sarcomas: a report of 17 cases of a newly defined entity. Mod Pathol 2018;31:674-84. [PMID: 29192652 DOI: 10.1038/modpathol.2017.162] [Cited by in Crossref: 97] [Cited by in F6Publishing: 101] [Article Influence: 16.2] [Reference Citation Analysis]
44 Busca A, Parra-Herran C. Myxoid Mesenchymal Tumors of the Uterus: An Update on Classification, Definitions, and Differential Diagnosis. Adv Anat Pathol 2017;24:354-61. [PMID: 28787279 DOI: 10.1097/PAP.0000000000000164] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 3.2] [Reference Citation Analysis]
45 Pickett JL, Chou A, Andrici JA, Clarkson A, Sioson L, Sheen A, Reagh J, Najdawi F, Kim Y, Riley D, Maidens J, Nevell D, McIlroy K, Valmadre S, Gard G, Hogg R, Turchini J, Robertson G, Friedlander M, Gill AJ. Inflammatory Myofibroblastic Tumors of the Female Genital Tract Are Under-recognized: A Low Threshold for ALK Immunohistochemistry Is Required. Am J Surg Pathol 2017;41:1433-42. [PMID: 28731868 DOI: 10.1097/PAS.0000000000000909] [Cited by in Crossref: 37] [Cited by in F6Publishing: 40] [Article Influence: 6.2] [Reference Citation Analysis]
46 Kerr S. Molecular Testing in Gynecologic Cancer. Diagnostic Molecular Pathology 2017. [DOI: 10.1016/b978-0-12-800886-7.00028-5] [Reference Citation Analysis]
47 Howitt BE, Nucci MR. Molecular Pathology of Uterine Mesenchymal Tumors. Molecular Pathology Library 2017. [DOI: 10.1007/978-3-319-57985-6_11] [Reference Citation Analysis]
48 Cong W, Ji Y, Lu X, Feng L, Jin G. Tumor-Like Lesions of the Liver and Intrahepatic Bile Duct. Surgical Pathology of Hepatobiliary Tumors 2017. [DOI: 10.1007/978-981-10-3536-4_5] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
49 Cao Q, Liu F, Li S, Liu N, Li L, Li C, Peng T. Primary rare anaplastic large cell lymphoma, ALK positive in small intestine: case report and review of the literature. Diagn Pathol. 2016;11:83. [PMID: 27612448 DOI: 10.1186/s13000-016-0539-6] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
50 Patne SC, Katiyar R, Chaudhary D, Trivedi S. Dysuria and fever in a young woman diagnosed as having inflammatory myofibroblastic tumour of the urinary bladder. BMJ Case Rep 2016;2016:bcr2015214059. [PMID: 26880824 DOI: 10.1136/bcr-2015-214059] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
51 Fletcher Prieto AV, Vega Forero DI, Acosta JA, Suescún Garay O, Beltrán MI. Tumor miofibroblástico de origen ovárico: comportamiento agresivo y fatal. Revista Colombiana de Cancerología 2016;20:40-44. [DOI: 10.1016/j.rccan.2015.11.005] [Reference Citation Analysis]
52 Subbiah V, McMahon C, Patel S, Zinner R, Silva EG, Elvin JA, Subbiah IM, Ohaji C, Ganeshan DM, Anand D, Levenback CF, Berry J, Brennan T, Chmielecki J, Chalmers ZR, Mayfield J, Miller VA, Stephens PJ, Ross JS, Ali SM. STUMP un"stumped": anti-tumor response to anaplastic lymphoma kinase (ALK) inhibitor based targeted therapy in uterine inflammatory myofibroblastic tumor with myxoid features harboring DCTN1-ALK fusion. J Hematol Oncol 2015;8:66. [PMID: 26062823 DOI: 10.1186/s13045-015-0160-2] [Cited by in Crossref: 57] [Cited by in F6Publishing: 59] [Article Influence: 7.1] [Reference Citation Analysis]
53 Soslow RA, Oliva E. Uterine Cancer: Pathology. Current Clinical Oncology 2015. [DOI: 10.1007/7631_2015_7] [Reference Citation Analysis]
54 Palacios J, Dal Cin P. Molecular Pathology and Cytogenetics of Endometrial Carcinoma, Carcinosarcoma, and Uterine Sarcomas. Current Clinical Oncology 2015. [DOI: 10.1007/7631_2015_6] [Reference Citation Analysis]